PHARMACEUTICAL AND COSMETIC COMPOSITIONS COMPRISING SECRETOMES

CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 63/020,250, filed May 5, 2020, which application is incorporated herein by reference in its entirety.

INCORPORATION BY REFERENCE

[0002] All publications, patents, and patent applications herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict between a term herein and a term in an incorporated reference, the term herein controls.

SUMMARY ~~OF THE INVENTION~~

[0003] The inventive embodiments provided in this Brief Summary of the Invention are meant to be illustrative only and to provide an overview of selective embodiments disclosed herein. The Brief Summary of the Invention, being illustrative and selective, does not limit the scope of any claim, does not provide the entire scope of inventive embodiments disclosed or contemplated herein, and should not be construed as limiting or constraining the scope of this disclosure or any claimed inventive embodiment.

[0003a] In one aspect, disclosed herein is a composition comprising 1) about 0.1% or more w/w of secretome and 2) a pharmaceutically or cosmetically acceptable excipient; wherein the secretome comprises MCP-1 and CXCL2 (GRO), and wherein the composition is free from a cell.

[0003b] In another aspect, disclosed herein is a use of the composition disclosed herein in the manufacture of a medicament for treating a skin condition in a subject in need thereof.

[0003c] In another aspect, disclosed herein is the composition disclosed herein for use in treating a skin condition in a subject in need thereof.

[0004] A secretome disclosed herein can comprise a chemokine, an interleukin, a growth factor, or any combination thereof. A secretome disclosed herein can comprise micro-vesicles, exosomes, or a combination thereof. In some of many aspects, disclosed herein is a composition, comprising 1) about 0.1% or more w/w of secretome and 2) a pharmaceutically or cosmetically acceptable excipient, wherein the secretome comprise monocyte chemoattractant protein-1 (MCP-1; CCL2), and wherein the composition is free from a cell. In some instances, the secretome comprises MCP-1 and one or more of Chemokine (C-X-C motif) ligand 2

(CXCL2; GRO), interleukin 6 (IL-6), IL-8, and vascular endothelial growth factor (VEGF) proteins. In some instances, the secretome comprises MCP-1 and two or more of CXCL2 (GRO), IL-6, IL-8, and VEGF proteins. In some instances, the secretome comprises MCP-1 and three or more of CXCL2 (GRO), IL-6, IL-8, and VEGF proteins. In some instances, the secretome comprises MCP-1 and all of CXCL2 (GRO), IL-6, IL-8, and VEGF proteins.

[0005] The secretome can comprise at least: 0.6%, 1%, 1.25%, 1.5%, 2%, 2.5%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the composition. In some instances, the secretome comprises about 0.6%, about 1%, about 1.25%, about 1.5%, about 2%, about 2.5%, about 3%, about 4%, about 5%, about 6%, about 7%, about